Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818 008 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
+44 1494 818 008

I would like to say a huge thank you for all of your recent hard work on my behalf which secured me a role at Urgo.
Naomi, 2011

Bayer HealthCare announces positive Nexavar thyroid cancer data

3 January 2013 11:28 in Pharmaceutical Company Product News

Bayer HealthCare and partner Onyx Pharmaceuticals have unveiled new clinical trial data showing the potential of Nexavar tablets to treat a certain form of cancer.

Results from the phase III Decision study demonstrated that Nexavar delivered progression-free survival benefits among patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.

The safety and tolerability profiles of the drug were also shown to be positive, suggesting Nexavar could be an effective therapy for a condition for which there are currently limited options available.

Bayer plans to submit the Decision data to support marketing authorisation applications for Nexavar in the treatment of RAI-refractory differentiated thyroid cancer.

Dr Dimitris Voliotis, vice-president for global clinical oncology development at Bayer HealthCare, said: "We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients."

This comes after the firm submitted radium-223 dichloride for European approval in the treatment of castration-resistant prostate cancer last month.ADNFCR-8000103-ID-801515813-ADNFCR

Other news stories from 03/01/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd